Quantifying DCK mRNA and protein expression and, more importantly, activity in lymphoid cells from MS patients undergoing 2CdA treatment will be crucial to identify T- and B-cell subsets potentially relevant to MS pathogenesis that are preferential targets for this drug. This evidence concerns the gene DCK and myeloid sarcoma.